Last updated: July 12, 2026

Application No. 19/422,028

Untitled Application

Unknown

Filed

Priority

Jun 29, 2023 — EU 23182238.8 +1 more

Examiner

IVANOVA, SVETLANA M

Art Unit

Tech Center

Hoffmann-La Roche Inc.

Assignee

Hoffmann-La Roche Inc.

OA Round

1 (Non-Final)

This examiner grants 51% of cases after interview

— +51.6% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 842 resolved cases, 2023–2026

Examiner Intelligence

IVANOVA, SVETLANA M View full profile →

Grants 51% of resolved cases

Career Allowance Rate

427 granted / 842 resolved

-9.3% vs TC avg

Strong +52% interview lift

Without

With

+51.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 8m

Avg Prosecution

34 currently pending

Career history

869

Total Applications

across all art units

Statute-Specific Performance

§101

0.9%

-39.1% vs TC avg

§103

60.5%

+20.5% vs TC avg

§102

7.9%

-32.1% vs TC avg

§112

13.9%

-26.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 842 resolved cases

Precedent Cases

Applications granted by this same examiner with similar technology

17/291,211

Patent 12673032

EXPLOITING ESTROGEN RECEPTOR BETA AND TP53 INTERACTION AS A NEW THERAPEUTIC STRATEGY FOR CANCER

5y 2m to grant Granted Jul 07, 2026

17/920,077

Patent 12667549

SYNERGISTIC ADMIXTURES OF GABAPENTIN AND KETOPROFEN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE

3y 8m to grant Granted Jun 30, 2026

17/908,876

Patent 12649709

NAPHTHOQUINONE-BASED CHALCONE DERIVATIVES AND USES THEREOF

3y 9m to grant Granted Jun 09, 2026

18/479,338

Patent 12636367

PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND

2y 7m to grant Granted May 26, 2026

17/622,210

Patent 12624015

JNK INHIBITORS AS ANTICANCER AGENTS

4y 4m to grant Granted May 12, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

51%

Grant Probability

99%

With Interview (+51.6%)

2y 8m

Median Time to Grant

Low

PTA Risk

Based on 842 resolved cases by this examiner. Grant probability derived from career allowance rate.